Navigation Links
Gene Therapy Corrected Rare Bleeding Disorder: Study
Date:12/6/2010

By Amanda Gardner
HealthDay Reporter

SUNDAY, Dec. 5 (HealthDay News) -- Using gene therapy, German researchers report that they managed to "correct" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.

However, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene. The boy is currently on chemotherapy, the study authors noted.

"This is a very good first step, but it's a little scary and we need to move to safer vectors," said Dr. Mary Ellen Conley, director of the Program in Genetic Immunodeficiencies at St. Jude Children's Research Hospital in Memphis, Tenn.

"The study shows proof-of-principle that gene therapy with stem cells in a genetic disorder like this has strong potential," added Paul Sanberg, a stem cell specialist who is director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa.

Neither Conley nor Sanberg were involved in the study, which is scheduled to be presented Sunday at the annual meeting of the American Society of Hematology in Orlando, Fla.

According to Conley, children (mostly boys) with Wiskott-Aldrich syndrome (WAS) are born with an inherited genetic defect on the X chromosome that affects the number and size of platelets and makes the children remarkably susceptible to easy bleeding and infections, including different types of cancer.

Bone marrow transplants are the main treatment for the disorder which, if they succeed, basically cure the patient.

"They grow up, go to college and they cause problems," said Conley. "But they're not an easy group of patients to transplant."

Even if a good match is found, transplant recipients can go on to have more problems with infections, such as graft-versus-host disease, in which the body basically rejects the foreign elements.

"One of the long-lasting complications is the kids couldn't do this, they couldn't do that, they see themselves as different," Conley said. "Transplants are getting better but we need better therapy, there's no question."

In this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the "granddaddy" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector. A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.

In fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.

"This is a first step that says you can correct the disease but I think most people would look at it and say the risk of leukemia is something, and that, let's see if we can avoid that," said Conley, whose team at St. Jude is working on a therapy involving a different type of vector. "It's a good start, but I think we have better things coming down the road."

In other news from the conference, another group of German researchers have determined that people who donate peripheral blood stem cells or bone marrow to help save a life don't face any heightened risk of cancer.

Previously there had been some concern that drugs needed to get the stem cells out of the bone marrow and into the bloodstream where they could be accessed might pose a risk of leukemia.

The study was based on questionnaires returned from more than 12,500 donors, which also showed the donors tended to be in good health and were willing to donate again.

Another study found that the drug rituximab (Rituxan), used to treat rheumatoid arthritis and forms of leukemia and lymphoma, could greatly reduce graft-versus-host disease in stem cell transplant recipients.

More information

The National Marrow Donor Program has more on Wiskott-Aldrich syndrome.

SOURCES: Mary Ellen Conley, M.D., director, program in genetic immunodeficiencies, St. Jude Children's Research Hospital, Memphis, Tenn.; Paul Sanberg, Ph.D., D.Sc., distinguished professor, neurosurgery, and director, University of South Florida Center of Excellence for Aging and Brain Repair, Tampa; Dec. 5, 2010, presentations, American Society of Hematology annual meeting, Orlando, Fla.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Worm Therapy Shows Promise for Ulcerative Colitis
2. Sixth global conference on stem cell therapy to be held Jan. 20-21, 2011, in New York City
3. Breast Cancer Rates Lower With Less Hormone Therapy: Study
4. Drop in breast cancer rates directly tied to reduced hormone therapy
5. Gene therapy prevents memory problems in mice with Alzheimers disease
6. Gene therapy for metastatic melanoma in mice produces complete remission
7. Neuralstem files FDA application for first drug therapy
8. Combination therapy improves survival time for patients with advanced liver cancer
9. Gene Therapy Shows Potential Against Heart Failure
10. Hearing loss common following radiation therapy for head and neck cancer
11. Targeted therapy reactivates guardian of the genome in resistant cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Therapy Corrected Rare Bleeding Disorder: Study 
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
(Date:4/28/2017)... ... ... People are starting to accept that hearing aids can be helpful and ... it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura Marks, ... American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid on ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... Manager for the North East region. Côté has 20+ years of experience within ... to Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Rob Lowe ... and now he has leant his presence to an educational purpose as the host ... one important one being cancer. In a recent episode, the series focuses on thyroid ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research Foundation is ... Nudge Guide," a groundbreaking analysis of how behavioral economics can be applied to ... to IRR programs, the report highlights proven behavioral economics approaches and the powerful ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology: